GP
XBI icon

GLG Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

GLG Partners’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-150,000
Closed -$8.11M – 515
2016
Q2 		$8.11M Sell
150,000
-1,850,000
-93% -$101M 0.24% 130
2016
Q1 		$103M Buy
+2,000,000
New +$104M 2.93% 2

Other funds holding XBI

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

GLG Partners's XBI Position: Q4 2017 in Review

GLG Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 34% in Q4 2017, buying an estimated $571K and bringing the position to 26,933 shares worth $2.29M. The position accounts for 0.11% of the portfolio, ranked #211.

GLG Partners first reported a position in XBI in Q1 2016 and has held it in 6 quarters since. The position peaked at $10.5M in Q2 2016. 397 funds tracked by Wall St. Rank hold XBI as of Q4 2017.

  • GLG Partners held 26,933 shares of State Street SPDR S&P Biotech ETF worth $2.29M as of Q4 2017.
  • GLG Partners bought 6,816 State Street SPDR S&P Biotech ETF shares in Q4 2017, an estimated $571K.
  • State Street SPDR S&P Biotech ETF made up 0.11% of GLG Partners's portfolio in Q4 2017, its #211 holding.
  • GLG Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and has held it in 6 quarters since.
  • GLG Partners's State Street SPDR S&P Biotech ETF position peaked at $10.5M in Q2 2016.
  • 397 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.